الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 179 |  |  |
| | | from | 179 | | |
Abstract
Fenoprofen calcium dihydrate (Nalfosab Capsules®) is a non-steroidal anti-inflammatory drug (NSAID). Fenoprofen calcium dihydrate has been widely applied in the treatment of inflammatory arthritis such as rheumatoid arthritis, gout and in osteoarthritis and has been shown to be efficacious and well tolerated. NSAIDs have provided an effective alternative approach to analgesic in the management of mild to moderate pain in several other painful conditions such as low back pain.
Fenoprofen calcium dihydrate produces their therapeutic action by inhibition of the cyclooxygenase (COX) enzyme, which is responsible for the synthesis of prostaglandins and related compounds. There are two forms of the COX enzyme, COX-1 and COX-2. COX-1 is found in most normal tissues, while COX-2 is induced in the presence of inflammation. Because COX-2 is not normally expressed in the stomach, the use of COX-2 inhibitors (e.g., rofecoxib, celecoxib) seems to result in less gastric ulceration than occurs with other anti-inflammatory analgesics. However, COX-2 inhibitors do not reduce the ability of platelets to form clots.
Fenoprofen calcium dihydrate is slightly soluble in water, with pka 4.5 at 25°C. It is readily absorbed from the gastrointestinal tract; bioavailability is about 85% but food and milk may reduce the rate and extent of absorption. Peak plasma concentrations of 50μg/ml occur one to two hours after a dose. The plasma half-life is about 3 hours. Fenoprofen calcium is about 99% bound to plasma proteins. About 90% of a dose is excreted in the urine in 24 hours.